http://hdl.handle.net/1765/30024
http://dx.doi.org/10.1183/09031936.00099306
pubmed: 18238951
scopus: 40649117704
http://dx.doi.org/10.1183/09031936.00099306
pubmed: 18238951
scopus: 40649117704
Outcomes for COPD pharmacological trials: From lung function to biomarkers
February 2008
Article
volume 31, issue 2 pp 416-468.
(Free full text at PubMed)
Repository contains one file which is not publicly available
The American Thoracic Society/European Respiratory Society jointly created a Task Force on "Outcomes for COPD pharmacological trials: from lung function to biomarkers" to inform the chronic obstructive pulmonary disease research community about the possible use and limitations of current outcomes and markers when evaluating the impact of a pharmacological therapy. Based on their review of the published literature, the following document has been prepared with individual sections that address specific outcomes and markers, and a final section that summarises their recommendations. Copyright
